Loss of bone mineral density (BMD) due to aromatase inhibitor therapy

Loss of bone mineral density due to aromatase inhibitor therapy, commonly referred to as aromatase inhibitor–associated bone loss, is a form of cancer treatment–induced skeletal demineralization characterized by rapid bone loss and an elevated risk of osteoporotic fractures

Loss of bone mineral density due to aromatase inhibitor therapy, commonly referred to as aromatase inhibitor–associated bone loss, is a form of cancer treatment–induced skeletal demineralization characterized by rapid bone loss and an elevated risk of osteoporotic fractures It predominantly affects postmenopausal women undergoing adjuvant endocrine therapy for hormone receptor–positive breast cancer This profound hypoestrogenic state accelerates osteoclast-mediated bone resorption, outpaces bone...

It predominantly affects postmenopausal women undergoing adjuvant endocrine therapy for hormone receptor–positive breast cancer Pathophysiologically, aromatase inhibitors inhibit the peripheral conversion of androgens to estrogens, resulting in near-total systemic estrogen depletion

Pathophysiologically, aromatase inhibitors inhibit the peripheral conversion of androgens to estrogens, resulting in near-total systemic estrogen depletion

This profound hypoestrogenic state accelerates osteoclast-mediated bone resorption, outpaces bone formation, and leads to deterioration of skeletal microarchitecture at rates significantly higher than normal postmenopausal bone loss

This profound hypoestrogenic state accelerates osteoclast-mediated bone resorption, outpaces bone formation, and leads to deterioration of skeletal microarchitecture at rates significantly higher than normal postmenopausal bone loss